BACKGROUND Heart failure guidelines recommend up-titration of angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) to doses used in randomized clinical trials, but these recommended doses are often not reached. Up-titration may, however, not be necessary in all patients. OBJECTIVES This study sought to establish the role of blood biomarkers to determine which patients should or should not be up-titrated. METHODS Clinical outcomes of 2,516 patients with worsening heart failure from the BIOSTAT-CHF (BIOlogy Study to Tailored Treatment in Chronic Heart Failure) were compared between 3 theoretical treatment scenarios: scenario A, in which all patients are up-titrated to >50% of recommended doses; scenario B, in which patients are up-titrated according to a biomarker-based treatment selection model; and scenario C, in which no patient is up-titrated to >50% of recommended doses. The study conducted multivariable Cox regression using 161 biomarkers and their interaction with treatment, weighted for treatment-indication bias to estimate the expected number of deaths or heart failure hospitalizations at 24 months for all 3 scenarios.
M ajor improvements in pharmaceutical and device heart failure treatment of heart failure have been achieved in the past year. Evidence from large randomized clinical trials demonstrates that angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and mineralocorticoid receptor antagonists (MRAs) improve clinical outcome in patients with mild-to-moderate heart failure (1) (2) (3) (4) (5) (6) (7) (8) . In large randomized clinical trials, treatment doses were up-titrated to pre-specified doses, which have become the guidelinerecommended doses (9) (10) (11) (12) . Despite these improvements and recommendations, the prognosis of patients with heart failure remains poor (13) (14) (15) (16) , and in daily clinical practice the majority of patients do not achieve recommended doses (17) (18) (19) . Although it is expected that most patients that achieve recommended doses will benefit from treatment, selected patients may not benefit from the recommended doses, but will experience side effects of ACE inhibitors and beta-blocker treatment. A personalized medicine approach in which patients who will not benefit from recommended ACE inhibitor/ARB and betablocker heart failure treatment might be selected by biomarkers, and might reduce the number of patients receiving treatment without benefit and improve overall outcome.
In this in silico study, we used data from the BIOSTAT-CHF (BIOlogy Study to Tailored Treatment in Chronic Heart Failure) project to identify such treatment selection markers. We hypothesized that biomarkers measured at baseline in serum or plasma of heart failure patients can identify whether patients benefit from recommended heart failure treatment or not. We developed models to estimate this benefit using 161 established and novel biomarkers, including standard biochemical blood parameters. We T r e a t m e n t b e n e fi t s t a t i s t i c s . We calculated the Table 1 . Most frequently selected biomarkers are reported in Online Table 2 . BUN, fibroblast growth factor 23, and pro-enkephalin were the strongest predictors of clinical events in patients that were successfully up-titrated with ACE inhibitors/ARBs. Serum creatinine, galectin-3, ST2, and albumin were the strongest predictors of clinical events in patients that were successfully up-titrated with beta-blockers (Online Table 3 Using both models, we were able to calculate survival probability at 24 months for both scenarios (successful or nonsuccessful up-titration). The scenario with the highest probability was considered the most beneficial one for the individual patient. In 2% (n ¼ 42) of patients, the highest probability was found in patients who were not successfully up-titrated with ACE inhibitors/ARBs. Characteristics of these patients are presented in Table 2 . Patients not benefitting from ACE inhibitor/ARB up-titration were younger, more frequently smokers, with less atrial fibrillation and higher hemoglobin and BUN, but lower heart rate and NT-proBNP levels. In 33% (n ¼ 592) of patients, the highest survival probability was found in patients who were not successfully uptitrated with beta-blockers. Characteristics of these patients are presented in Table 2 . Patients not benefitting from beta-blocker up-titration were older, leaner, and more frequently smokers or former smokers. They also had less ischemic heart failure, but more myocardial infarction, and other comorbidities. in Figure 1 . Values are n, mean AE SD, n (%), or median (interquartile range). Table 1 . Values are % or n (95% confidence interval). Scenario A was if all patients were successfully up-titrated to >50% of recommended dose, scenario B was if up-titration was based on the biomarker treatment selection model, and scenario C was if no patient was successfully up-titrated for ACE inhibitors/ARBs. Table 1 . 
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DISCUSSION
We hypothesized that not every patient with heart failure with reduced ejection fraction will benefit from maximal up-titration with either ACE inhibitors/ ARBs or beta-blockers. We therefore tested 3 hypo- There are many biomarkers known to influence therapeutic response and survival (26, 27) , and there have been many attempts to use biomarker levels for evaluating treatment response and outcome (28) .
However, no models were developed using a multi- Because not all biomarkers used in our treatment selection models were measured in the validation cohort of the BIOSTAT-CHF study of 1,728 patients, we unfortunately could not validate our results in this cohort. In the future, and when funding is available we aim to measure the missing biomarkers and validate our treatment selection models in this cohort as well.
We found substantial differences between patients of which the model assumed not to benefit from 
